14 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
27839918	28	Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK).	Takeda California, Inc.
27288183	130	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.	Southeast University
26762835	342	Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2).	Icahn School of Medicine at Mount Sinai
23489211	44	Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor.	Universit£ degli Studi di Parma
18183025	12060	A quantitative analysis of kinase inhibitor selectivity.	Ambit Biosciences
22014550	337	Discovery of a novel class of non-ATP site DFG-out state p38 inhibitors utilizing computationally assisted virtual fragment-based drug design (vFBDD).	Ansaris
22018461	41	Novel tricyclic inhibitors of IKK2: discovery and SAR leading to the identification of 2-methoxy-N-((6-(1-methyl-4-(methylamino)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-7-yl)pyridin-2-yl)methyl)acetamide (BMS-066).	Bristol-Myers Squibb Research and Development
22037378	31824	Comprehensive analysis of kinase inhibitor selectivity.	Ambit Biosciences
20961062	42	Indazolylpyrazolopyrimidine as highly potent B-Raf inhibitors with in vivo activity.	Pfizer Inc.
19654408	2521	AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).	Ambit Biosciences
19788238	36	Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4).	University of Zurich
19035792	85	Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.	GlaxoSmithKline